Introduction: Spatial dose distribution around the radionuclides sources is required for optimized treatment planning in radioimmunotherapy. At present, the main source of data for cellular dosimetry is the s-values provided by MIRD. However, the MIRD s-values have been calculated based on analytical formula in which no electrons straggling is taken to account. In this study, we used Geant4-DNA...

introduction: spatial dose distribution around the radionuclides sources is required for optimized treatment planning in radioimmunotherapy. at present, the main source of data for cellular dosimetry is the s-values provided by mird. however, the mird s-values have been calculated based on analytical formula in which no electrons straggling is taken to account. in this study, we used geant4-dna...

Background: Radioiodine is routinely used or proposed for diagnostic and therapeutic purposes: I, I and I for diagnostics and I and I for therapy. When radioiodine-labelled pharmaceuticals are administered to the body, radioiodide might be released into the circulation and taken up by the thyroid gland, which may then be an organ at risk. The aim of this study was to compare dosimetric properti...

Therapy with 90Y-microspheres is emerging as a mainstream treatment modality in the management of patients with primary and metastatic liver cancer (1,2). The technique involves the administration of 90Y-microspheres into the hepatic artery, which is accessed via the transfemoral route or through a hepatic arterial infusion port or pump. The technique was first introduced by Ariel, who also rep...

UNLABELLED The contribution to red marrow absorbed dose from beta-emitting radionuclides distributed uniformly in the total body can be overestimated using either MIRD 11 or MIRDOSE3. The S value assigned to the red marrow target region from activity distributed in the remainder of the body is of particular concern. The assumption that the specific absorbed fraction for total body irradiating r...

68 Objective: In this study, we tried to estimate human absorbed dose of Ga-NODAGA-glycine as a new potential positron emission tomography (PET) renal agent based on the biodistribution data reported in healthy rats, and compare our estimation with the available absorbed dose data from technetium-99m-diethy99m lenetriaminepentaacetic acid ( Tc-DTPA). Subjects and Methods: The medical internal r...

The manuscripts included in this special issue of Cancer Biotherapy & Radiopharmaceuticals highlight current data and theoretical foundations regarding dose–response relationships related to radionuclide therapy kidney toxicity. With the use of the kidney dosimetry model presented in MIRD 19,1 these experimental and clinical data, when correlated with accurate regional dose information, may pro...

Mathematical models for kinetics of radiopharmaceuticals in humans were developed and are used to estimate the radiation absorbed dose for patients in nuclear medicine by the International Commission on Radiological Protection and the Medical Internal Radiation Dose (MIRD) Committee. However, due to the fact that the residence times used were derived from different subjects, partially even with...